Shire
Shire’s Cinryze gets FDA fast track designation
October 13, 2015Research and Development AMR, FDA, Shire
Shire has announced that the United States Food and Drug Administration (FDA) has granted fast track designation for the investigation …
Shire ADHD treatment Intuniv gets EU approval
September 21, 2015Sales and Marketing ADHD, Shire, attention deficit hyperactivity disorder, intuniv
The European Commission has granted marketing authorisation for Shire’s Intuniv for the treatment of ADHD in children. Intuniv (guanfacine hydrochloride prolonged …
Actelion confirms takeover talks with ZS Pharma
September 11, 2015Research and Development, Sales and Marketing Actelion, Shire, ZS Pharma, mergers and acquisitions
Swiss drugmaker Actelion has entered discussions with US biotech company ZS Pharma, over a takeover thought to be worth $2.5 …
Shire appoints Sara Mathew to board of directors
September 2, 2015Manufacturing and Production, Research and Development, Sales and Marketing Sara Mathew, Shire
Shire has appointed Sara Mathew to its board of directors as a non-executive director.Mathew will also be a member of …
Shire goes public with rejected $30bn Baxalta bid
August 5, 2015Research and Development, Sales and Marketing Baxalta, Shire, acquisitions, baxter, mergers, rare disease
Shire has confirmed that it made an all-share $30 billion offer to buy Baxalta last month, citing ’a strong strategic …
Shire in $300m Foresight acquisition
August 4, 2015Manufacturing and Production, Research and Development, Sales and Marketing FST-100, Foresight Biotherapeutics, Shire, conjunctivitis, dry eye, lifitegrast, pink eye
Shire has acquired Foresight Biotherapeutics for $300 million, as it looks to build its presence in eye diseases. The acquisition …
Overcoming barriers in rare diseases
June 22, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BIA, NHS, Shire, bates, government, nps, rare diseases
In recent months the focus on the need to develop new drugs and fund new treatments for rare diseases has …
Shire makes £12 billion move for Actelion
June 8, 2015Sales and Marketing Actelion, Shire, brett wells, nps pharma
Not a week goes by without a big pharma merger story, and now it’s the turn of Dublin-headquartered Shire that …
Shire earns EMA nod for constipation drug
June 3, 2015Sales and Marketing EMA, Resolor, Shire, constipation
Shire has seen approval from the European Medicines Agency to extend the licence of its constipation drug Resolor for men …
New chief financial officer for Shire
May 12, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shire, jeff poulton
Irish pharma firm Shire has appointed a new chief financial officer and member of its executive committee in Jeff Poulton. …
Alexion makes $8.4 billion Synageva purchase
May 7, 2015Research and Development, Sales and Marketing Alexion, Shire, nps, rare disease, synageva
Rare disease specialist firm Alexion is splashing out $8.4 billion to buy fellow US orphan drug developer Synageva biopharmaceuticals. The …
Shire gets FDA boost – but suffers trial setback
April 10, 2015Research and Development, Sales and Marketing FDA, Shire, algs, lifitegrast, shp625
Shire has achieved mixed results in its attempts to get regulatory approval for two new treatments – bagging a priority …
Shire plots new ADHD drug approval
April 7, 2015Sales and Marketing ADHD, FDA, SHP465, Shire, Vyvanse, clinical trials, paediatrics
Shire is launching a new clinical trial as part of its FDA submission for a potential ADHD treatment. The company …
Shire to buy Meritage Pharma
February 25, 2015Research and Development, Sales and Marketing AbbVie, Meritage Pharma, Shire, eoe, gastrointestinal
Shire has purchased Meritage Pharma, a privately-held company specialising in gastrointestinal and skin diseases for $70 million. The acquisition means …
Latest content
